These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 16098822

  • 1. Fluid retention mediated by renal PPARgamma.
    Staels B.
    Cell Metab; 2005 Aug; 2(2):77-8. PubMed ID: 16098822
    [Abstract] [Full Text] [Related]

  • 2. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
    Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD.
    Nat Med; 2005 Aug; 11(8):861-6. PubMed ID: 16007095
    [Abstract] [Full Text] [Related]

  • 3. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD.
    Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
    [Abstract] [Full Text] [Related]

  • 4. Kidney-specific gene targeting: insight into thiazolidinedione-induced fluid retention.
    Yang T.
    Nephrology (Carlton); 2006 Jun; 11(3):201-6. PubMed ID: 16756632
    [Abstract] [Full Text] [Related]

  • 5. PPARgamma agonists, modulation of ion transporters, and fluid retention.
    Nofziger C, Blazer-Yost BL.
    J Am Soc Nephrol; 2009 Dec; 20(12):2481-3. PubMed ID: 19820124
    [No Abstract] [Full Text] [Related]

  • 6. Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats.
    Yoshioka K, Wakino S, Homma K, Kanda T, Tatematsu S, Hasegawa K, Sugano N, Ito O, Omata K, Saruta T, Hayashi K.
    Obesity (Silver Spring); 2008 May; 16(5):965-71. PubMed ID: 18277387
    [Abstract] [Full Text] [Related]

  • 7. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

  • 8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 9. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M, Wolf G.
    Am J Nephrol; 2007 Apr 14; 27(4):425-34. PubMed ID: 17622750
    [Abstract] [Full Text] [Related]

  • 10. PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules.
    Fu Y, Gerasimova M, Batz F, Kuczkowski A, Alam Y, Sanders PW, Ronzaud C, Hummler E, Vallon V.
    Nephron; 2015 Apr 14; 129(1):68-74. PubMed ID: 25531136
    [Abstract] [Full Text] [Related]

  • 11. Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.
    Zhou L, Liu G, Jia Z, Yang KT, Sun Y, Kakizoe Y, Liu M, Zhou S, Chen R, Yang B, Yang T.
    Am J Physiol Renal Physiol; 2013 Nov 15; 305(10):F1491-7. PubMed ID: 24005472
    [Abstract] [Full Text] [Related]

  • 12. Paradoxes of body fluid volume regulation in health and disease. A unifying hypothesis.
    Schrier RW, Niederberger M.
    West J Med; 1994 Oct 15; 161(4):393-408. PubMed ID: 7817551
    [Abstract] [Full Text] [Related]

  • 13. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT, Sharma AM.
    Vascul Pharmacol; 2006 Jul 15; 45(1):46-53. PubMed ID: 16713364
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.
    Mao Z, Ong AC.
    Nephron Clin Pract; 2009 Jul 15; 112(4):c230-41. PubMed ID: 19546582
    [Abstract] [Full Text] [Related]

  • 15. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N, Walcher D.
    Prog Lipid Res; 2007 Nov 15; 46(6):283-96. PubMed ID: 17637478
    [Abstract] [Full Text] [Related]

  • 16. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
    Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, Ordway N, Dracopoli NC, Delmonte T, Hui L, Krishnan B, Cosma G, Ranade K.
    Pharmacogenet Genomics; 2008 Oct 15; 18(10):903-10. PubMed ID: 18794727
    [Abstract] [Full Text] [Related]

  • 17. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM.
    Eur J Pharmacol; 2008 Oct 31; 596(1-3):173-9. PubMed ID: 18761337
    [Abstract] [Full Text] [Related]

  • 18. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model.
    Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM, Feingold KR.
    Exp Dermatol; 2006 Mar 31; 15(3):154-60. PubMed ID: 16480422
    [Abstract] [Full Text] [Related]

  • 19. Maintenance of Kidney Metabolic Homeostasis by PPAR Gamma.
    Corrales P, Izquierdo-Lahuerta A, Medina-Gómez G.
    Int J Mol Sci; 2018 Jul 16; 19(7):. PubMed ID: 30012954
    [Abstract] [Full Text] [Related]

  • 20. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J, Zhang D, Li J, Zhang X, Fan F, Guan Y.
    Clin Sci (Lond); 2009 Jan 16; 116(1):17-26. PubMed ID: 19037881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.